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adenosine acts on the e: erent arteriole, via 
A 2 AR, to dilate this segment. * is would 
result in reduced P GC and thus lower the 
GFR. This represents a supplementary 
mechanism to lower GFR in addition to the 
well-established A 1 AR e: ect in the a: erent 
arteriole. * erefore, activation of adenosine 
release, which is linked to the increased 
solute delivery, would act at two di: erent 
vascular sites. * e e: ects of adenosine on 
these vessels are dependent on the receptors 
expressed in each arteriole. 
 How does this new information add 
to the concept that adenosine regulates 
TGF, vascular tone, and ultimately glomeru-
lar filtration under normal conditions? 
Static input to the macula densa of solute 
load activating the Na   +   / K   +   / 2Cl   −   (NKCC) 
transporter requires generation of ATP via 
Na   +   / K   +   ATPase on the basolateral mem-
branes. Inter- and extracellular nucleotidases 
form adenosine that acts on receptors in the 
vascular bed. The relative expression of 
A 1 AR versus A 2 ARs will dictate the vascular 
response. * erefore, small changes to solute 
input result in sensitive changes in vascular 
tone. * ese new data from Al-Mashhadi 
 et al. 1 support the concept that adenosine is 
signaling to both arterioles, with the same 
e: ect to reduce GFR ( Figure 1 ). 
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 Left ventricular hypertrophy 
in renal disease: 
beyond preload and afterload 
 Eberhard  Ritz 1 
 To explain ventricular concentric and / or eccentric hypertrophy in 
chronic kidney disease, past studies suggested that this was the result of 
increased preload and / or afterload. Using a renal ablation model of the 
mouse with documented absence of hypertension, Siedlecki  et al. 
provide evidence for the involvement of the mammalian target of 
rapamycin (mTOR) pathway. This suggests that load-independent 
primary stimuli trigger or contribute to ventricular hypertrophy and 
fibrosis in uremia. 
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 Since the seminal observation of Richard 
Bright (1789 – 1858), cardiac hypertrophy 
has been known as a characteristic 
component of chronic kidney disease. 
In addition, the brilliant experimental 
studies of Traube (1818 – 1876) docu-
mented that renal damage is associated 
with hypertension as the putative cause of 
cardiac hypertrophy. But is hypertension 
and hypervolemia all there is to cardiac 
hypertrophy in chronic kidney disease? 
 * e past simple concept that cardiac 
hypertrophy in uremia is the result of 
increased a4 erload and preload is no 
longer consistent with the result of an 
experimental study: after subtotal 
nephrectomy, increased dry weight and 
calcium content were documented for the 
right ventricle and for the le4  ventricle 
even when intra-arterial blood pressure in 
conscious animals was normal and when 
sympathetic overactivity, anemia, hyper-
parathyroidism, and so on were pre-
vented. 1 The involvement of the right 
ventricle points to some  systemic factor. 
Interestingly, changes in the isomyosin 
pattern were noted as well. 
 * ere is an ongoing discussion in cardi-
ology about whether physiological hyper-
trophy (as an adaptive response to growth 
signals) di: ers from pathological hyper-
trophy (developing in response to stress 
signals such as increased pre- and a4 er-
load). 2 This is more than an academic 
issue because, as Frey  et al. 2 have pointed 
out, it raises the question of whether car-
diac hypertrophy per se might become a 
potential therapeutic target. 
 Researchers have identified a spec-
trum of signaling pathways that play a role 
in the genesis of di: erent forms of cardiac 
hypertrophy, 2,3 mainly:  
 
     i.  The calcium calcineurin / NFAT 
(nuclear factor of activated T cells) 
pathway; 
   ii.  * e pathway mediated via G pro-
tein-coupled receptors, that is, 
adrenergic, angiotensin, and 
endothelin signals; 
 iii.  * e phosphoinositide 3-kinase / Akt 
(protein kinase B) / glycogen syn-
thase kinase-3 pathway; 
   iv.  Peroxisome proliferator-activated 
receptor (PPAR); 
     v.  * e small G-protein pathway (Rho 
family). 
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 Two experimental studies addressed the 
issue of the signaling pathways involved 
in cardiac hypertrophy of renal failure 
and identi ed two pathways. Years ago 
Scheuer  et al. observed an acute increase 
of inotropy and depression of sarcolem-
mal Na   +   K   +   ATPase activity a4 er total or 
subtotal nephrectomy, 4 presumably 
explained by the now well-identified 
accumulation of Na   +   K   +   ATPase inhibi-
tors in uremia. Kennedy  et al. 5 tested the 
hypothesis that marinobufagenin, a cir-
culating inhibitor of Na   +   K   +   ATPase, is 
involved in the cardiomyopathy of 
 hypertensive uremic rats. Infusion of 
marinobufagenin caused the same 
changes as subtotal nephrectomy; that is, 
it caused an increase in cardiac weight, 
impairment of ventricular relaxation, 
diminished activity of sarcoplasmic retic-
ulum ATPase, cardiac  brosis, and oxi-
dant stress — all of which were antagonized 
by neutralizing antibodies against 
marino-bufagenin. Both partial nephrec-
tomy and marinobufagenin initiated a 
signaling cascade involving Ras and acti-
vation of extracellular signal-regulated 
kinase (ERK), leading to the generation 
of reactive oxygen species and decreased 
expression of Na   +   K   +   ATPase as well as 
sarcoplasmic reticulum Ca   +   +   ATPase. 
 Siedlecki  et al. 6 (this issue) report on a 
mouse model, a wise decision that opens 
the future possibility of studying geneti-
cally modi ed animals; instead of the fre-
quently used model of vascular ligation, 
they performed surgical resection of kid-
ney parenchyma, which avoids excessive 
activation of the renin – angiotensin sys-
tem as a confounder. * eir mice with mild 
impairment of renal function were nor-
motensive by invasive methodology — one 
caveat: the animals were anesthetized — so 
that preload and a4 erload could largely, 
but not absolutely, be excluded as a causal 
trigger. * e parallel development of pro-
gressive cardiac hypertrophy and  brosis 
(the latter was not speci cally investigated 
and commented upon) is important, as 
 brosis and capillary rarefaction 7 contrib-
ute in a major way to diastolic malfunc-
tion and electrical instability of the heart 
in uremia.  De novo protein synthesis is a 
precondition for the development of 
hypertrophy; consequently, the authors 
assessed and documented phosphorylation 
and activation of ERK1 / 2 and phosphor-
ylation of ribosomal S-6-kinase and 4E-
Bp1 — hallmarks of the activation of the 
mammalian target of rapamycin (mTOR) 
pathway. * is prompted the authors to 
suspect that mTOR is involved in the 
development of cardiac hypertrophy in 
this model. * e proof of the pudding is in 
its eating; so the authors administered the 
mTOR inhibitor rapamycin, and rapamy-
cin prevented cardiac hypertrophy in this 
uremic mouse model. 
 The mTOR pathway is activated by 
upstream signaling, that is, phospho-
inositide 3-kinase and Akt (protein kinase 
B). * e tuberous sclerosis genes  TSC1 and 
 TSC2 (unregulated constitutive activation 
of which underlies tuberous sclerosis) are 
the main regulators of the mTOR pathway. 
As a note of caution, however, blockade of 
the mTOR pathway by rapamycin does 
not fully block mTOR activation in car-
diomyocytes; this points potentially to an 
additional role of mTOR-independent 
pathways as well. 3 
 Involvement of the mTOR pathway in 
cardiac hypertrophy is not restricted to 
the model of uremia. In a variety of exper-
imental models of cardiac hypertrophy as 
well as in cardiomyocyte cultures, activa-
tion of the mTOR pathway has been dem-
onstrated. 8 Siedlecki  et al. 6 correctly point 
to the theoretical possibility that targeting 
the mTOR pathway may prevent or even 
reverse cardiac hypertrophy. Why would 
the possibility of preventing cardiac 
hypertrophy be so desirable? Unfortu-
nately, in its initial adaptive stages, cardiac 
hypertrophy increases the eI  cacy of car-
diac work and overcomes increased 
preload and a4 erload. In the long term, a 
maladaptive stage emerges that predis-
poses to heart failure and sudden death, 
which are the major causes of death in 
patients with end-stage kidney disease. 
 * erefore it is of considerable interest 
that prevention or reversal of cardiac 
hypertrophy by rapamycin has been 
observed a4 er kidney and heart trans-
plantation. 9 Unfortunately, the many side 
e: ects of the parent substance (for exam-
ple, hyperlipidemia, defective wound 
healing, edema, bacterial infections, pro-
teinuria) preclude its use for this indica-
tion, but analogues targeting the mTOR 
pathway that are devoid of such side e: ects 
are on the horizon. 10 * e enthusiasm is 
somewhat dampened by the fact that 
 Figure 1  |  The pathogenetic pathway for cardiac hypertrophy and fibrosis independent of 
the classical paradigm of increased preload and / or afterload. mTOR, mammalian target of 
rapamycin. 
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mTOR blockade increases the activity of 
upstream Akt (protein kinase B), counter-
acting the e: ect of the blockade. 
 As interesting as clari cation of these 
path ways in the genesis of cardiac hyper-
trophy is, it still raises the question of the 
upstream signals that trigger cardiac hy-
pertrophy in the  rst place, be it in response 
to increased preload and a4 erload or — as 
the data of Siedlecki  et al. 6 suggest — in 
response to other signals ( Figure 1 ). 
 Going beyond the above methodology, 
exciting progress has recently been made 
to clarify the molecular mechanisms 
underlying cardiac hypertrophy and car-
diac electrical instability. The hyper-
trophic growth response of adult 
cardiomyocytes is characterized by 
increased cell size, enhanced protein syn-
thesis, assembly of sarcomeres, and reac-
tivation of fetal genes — a concerted 
restructuring. * e crucial role of micro-
RNAs (miRNAs) in the modi cation of 
the cellular phenotype has recently been 
clearly proven. miRNAs are noncoding 
RNAs of 18 – 25 nucleotides that regulate 
gene expression. * ey are transcribed by 
RNA-polymerase II as large transcripts 
and are subsequently processed into 
smaller functional RNA fragments of 
18 – 25 nucleotides, which are highly con-
served in evolution; which orchestrate 
growth, development, function, and stress 
response of the heart; and which are 
viewed as potential therapeutic targets on 
the horizon. 11 In addition to the 
 conventional concept that genes encod-
ing proteins are the main regulators of 
cardiac growth, stress-responsive 
 miRNAs provide an additional powerful 
layer of control. * e miRNAs do not tar-
get single transcripts; regulatory networks 
are targeted by speci c miRNAs, and sig-
nature patterns — for example miR-24, 
miR-125b, miR-199a, miR-214, and miR-
195 in humans — are upregulated during 
cardiac hypertrophy. miRNAs act by deg-
radation of mRNA or inhibition of trans-
lation. 11 Increased miRNA expression 
also has been observed in human heart 
failure, and the e: ects can be reproduced 
in cardiomyocyte cultures. 
 Another level of control is modulation 
of gene expression by acetylation /
 deacetylation of histones; acetylation 
relaxes chromatin structure and allows 
access of transcription factors, whereas 
deacetylation promotes chromatin 
condensation and transcription or 
repression. 12 
 * ese topics, with the available meth-
odology, wait to be applied to the issue of 
cardiac hypertrophy in uremia. 
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